Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

RNAi Therapy Reduces Huntington's Disease Symptoms in Mouse Model

By BiotechDaily International staff writers
Posted on 01 Jun 2014
A research team used advanced gene therapy techniques to block the production of huntingtin (Htt), the toxic protein found in the brains of patients suffering from the fatal, inherited neurodegenerative disorder, Huntington's disease (HD).

Huntington’s disease is caused by a dominant gene that encodes the huntingtin protein. The 5' end of the HD gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine, that is repeated multiple times. Normal persons have a CAG repeat count of between seven and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of huntingtin is broken down into toxic peptides, which contribute to the pathology of the syndrome.

RNA interference (RNAi) therapy that seeks to selectively reduce the expression of Htt has emerged as a potential therapeutic strategy for this disorder. Investigators at the bio-therapeutics research company Genzyme (Framingham, MA, USA) have continued this approach by aiming to lower Htt levels and to correct the behavioral, biochemical, and neuropathological deficits shown to be associated with the YAC128 mouse model of Huntington's disease. To do this they treated these animals with a recombinant adeno-associated viral (AAV) vector that had been designed to deliver siRNA that targeted the degradation of the Htt transcript.

Results that support the continued development of AAV-mediated RNAi as a therapeutic strategy for HD were published in the May 21, 2014, issue of the journal Human Gene Therapy. They revealed that AAV-mediated RNAi was effective at transducing greater than 80% of the cells in the striatum and partially reducing the levels (by about 40%) of both wild-type and mutant Htt in this region. Concomitant with these reductions were significant improvements in behavioral deficits, reduction of striatal Htt aggregates, and partial correction of the aberrant striatal transcriptional profile observed in YAC128 mice.

Of particular importance was the finding that a partial reduction of both the mutant and wild-type Htt levels was not associated with any notable overt neurotoxicity.

Related Links:
Genzyme



Channels

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.